stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.65
0.23
+2.44%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Total debt
Telix Pharmaceuticals Limited's total debt at the end of fiscal 2025 was $461.6M, up 28.7% from $358.6M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $575.9M. Telix Pharmaceuticals Limited ranks 27th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $461.6M | 28.71% |
| FY2024 | $358.6M | 3,103.30% |
| FY2023 | $11.2M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $575.9M | 24.78% |
| Dec 2025 | $461.6M | 12.61% |
| Jun 2025 | $409.9M | 13.95% |
| Dec 2024 | $359.7M | 2,591.43% |
| 2 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| CELC Celcuity, Inc. compare | $753.2M |
| TLX Telix Pharmaceuticals Limited | $575.9M |
| VKTX Viking Therapeutics, Inc. compare | $250.7M |
| VRDN Viridian Therapeutics, Inc. compare | $242.2M |
| DYN Dyne Therapeutics, Inc. compare | $213.5M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $72.9M |
| DNLI Denali Therapeutics Inc. compare | $5.4M |
| IDYA IDEAYA Biosciences, Inc. compare | $2.1M |
| ELVN Enliven Therapeutics, Inc. compare | $445.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt